The 18-kDa Translocator Protein (TSPO) Disrupts Mammary Epithelial Morphogenesis and Promotes Breast Cancer Cell Migration

PLoS ONE

Volumn 8, Issue 8, 2013, Pages

  Wu, Xiaoting ^a   Gallo, Kathleen A ^a  

^a MICHIGAN STATE UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4' CHLORODIAZEPAM; CARRIER PROTEIN; ESTROGEN RECEPTOR; LONIDAMINE; N SEC BUTYL 1 (2 CHLOROPHENYL) N METHYL 3 ISOQUINOLINECARBOXAMIDE; TSPO PROTEIN; UNCLASSIFIED DRUG;

ACINAR CELL; APOPTOSIS; ARTICLE; BREAST CANCER; BREAST CELL; BREAST DEVELOPMENT; BREAST EPITHELIUM; CANCER CELL; CANCER GROWTH; CELL MIGRATION; CONTROLLED STUDY; DRUG POTENTIATION; DRUG TARGETING; EPITHELIUM CELL; GENE OVEREXPRESSION; GENE SILENCING; HUMAN; HUMAN CELL; MAMMARY EPITHELIAL MORPHOGENESIS; PROTEIN FUNCTION; TSPO GENE;

ACINAR CELLS; APOPTOSIS; BENZODIAZEPINONES; BREAST NEOPLASMS; CELL LINE, TUMOR; CELL MOVEMENT; CELL PROLIFERATION; CELL SIZE; DISEASE PROGRESSION; HUMANS; INDAZOLES; ISOQUINOLINES; LIGANDS; MAMMARY GLANDS, HUMAN; NEOPLASM INVASIVENESS; RECEPTORS, GABA;

EID: 84881540151     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0071258     Document Type: Article

References (43)

1. Hutchinson L, (2010) Breast cancer: challenges, controversies, breakthroughs. Nat Rev Clin Oncol 7: 669-670.
2. Rochefort H, Glondu M, Sahla ME, Platet N, Garcia M, (2003) How to target estrogen receptor-negative breast cancer? Endocr Relat Cancer 10: 261-266.
3. Putti TC, El-Rehim DM, Rakha EA, Paish CE, Lee AH, et al. (2005) Estrogen receptor-negative breast carcinomas: a review of morphology and immunophenotypical analysis. Mod Pathol 18: 26-35.
4. Reddy KB, (2011) Triple-negative breast cancers: an updated review on treatment options. Curr Oncol 18: e173-179.
5. Fulda S, Galluzzi L, Kroemer G, (2010) Targeting mitochondria for cancer therapy. Nat Rev Drug Discov 9: 447-464.
6. Hanahan D, Weinberg RA, (2011) Hallmarks of cancer: the next generation. Cell 144: 646-674.
7. Galluzzi L, Morselli E, Kepp O, Vitale I, Rigoni A, et al. (2010) Mitochondrial gateways to cancer. Mol Aspects Med 31: 1-20.
8. Papadopoulos V, Baraldi M, Guilarte TR, Knudsen TB, Lacapere JJ, et al. (2006) Translocator protein (18kDa): new nomenclature for the peripheral-type benzodiazepine receptor based on its structure and molecular function. Trends Pharmacol Sci 27: 402-409.
9. Rone MB, Liu J, Blonder J, Ye X, Veenstra TD, et al. (2009) Targeting and insertion of the cholesterol-binding translocator protein into the outer mitochondrial membrane. Biochemistry 48: 6909-6920.
10. Azarashvili T, Grachev D, Krestinina O, Evtodienko Y, Yurkov I, et al. (2007) The peripheral-type benzodiazepine receptor is involved in control of Ca2+-induced permeability transition pore opening in rat brain mitochondria. Cell Calcium 42: 27-39.
11. Choi J, Ifuku M, Noda M, Guilarte TR, (2011) Translocator protein (18 kDa)/peripheral benzodiazepine receptor specific ligands induce microglia functions consistent with an activated state. Glia 59: 219-230.
12. Veenman L, Shandalov Y, Gavish M, (2008) VDAC activation by the 18 kDa translocator protein (TSPO), implications for apoptosis. J Bioenerg Biomembr 40: 199-205.
13. Galiegue S, Casellas P, Kramar A, Tinel N, Simony-Lafontaine J, (2004) Immunohistochemical assessment of the peripheral benzodiazepine receptor in breast cancer and its relationship with survival. Clin Cancer Res 10: 2058-2064.
14. Batarseh A, Papadopoulos V, (2010) Regulation of translocator protein 18 kDa (TSPO) expression in health and disease states. Mol Cell Endocrinol 327: 1-12.
15. Han Z, Slack RS, Li W, Papadopoulos V, (2003) Expression of peripheral benzodiazepine receptor (PBR) in human tumors: relationship to breast, colorectal, and prostate tumor progression. J Recept Signal Transduct Res 23: 225-238.
16. Hardwick M, Fertikh D, Culty M, Li H, Vidic B, et al. (1999) Peripheral-type benzodiazepine receptor (PBR) in human breast cancer: correlation of breast cancer cell aggressive phenotype with PBR expression, nuclear localization, and PBR-mediated cell proliferation and nuclear transport of cholesterol. Cancer Res 59: 831-842.
17. Beinlich A, Strohmeier R, Kaufmann M, Kuhl H, (2000) Relation of cell proliferation to expression of peripheral benzodiazepine receptors in human breast cancer cell lines. Biochem Pharmacol 60: 397-402.
18. Li W, Hardwick MJ, Rosenthal D, Culty M, Papadopoulos V, (2007) Peripheral-type benzodiazepine receptor overexpression and knockdown in human breast cancer cells indicate its prominent role in tumor cell proliferation. Biochem Pharmacol 73: 491-503.
19. Carmel I, Fares FA, Leschiner S, Scherubl H, Weisinger G, et al. (1999) Peripheral-type benzodiazepine receptors in the regulation of proliferation of MCF-7 human breast carcinoma cell line. Biochem Pharmacol 58: 273-278.
20. Hirsch T, Decaudin D, Susin SA, Marchetti P, Larochette N, et al. (1998) PK11195, a ligand of the mitochondrial benzodiazepine receptor, facilitates the induction of apoptosis and reverses Bcl-2-mediated cytoprotection. Exp Cell Res 241: 426-434.
21. Sutter AP, Maaser K, Grabowski P, Bradacs G, Vormbrock K, et al. (2004) Peripheral benzodiazepine receptor ligands induce apoptosis and cell cycle arrest in human hepatocellular carcinoma cells and enhance chemosensitivity to paclitaxel, docetaxel, doxorubicin and the Bcl-2 inhibitor HA14-1. J Hepatol 41: 799-807.
22. Decaudin D, Castedo M, Nemati F, Beurdeley-Thomas A, De Pinieux G, et al. (2002) Peripheral benzodiazepine receptor ligands reverse apoptosis resistance of cancer cells in vitro and in vivo. Cancer Res 62: 1388-1393.
23. Debnath J, Muthuswamy SK, Brugge JS, (2003) Morphogenesis and oncogenesis of MCF-10A mammary epithelial acini grown in three-dimensional basement membrane cultures. Methods 30: 256-268.
24. Debnath J, Brugge JS, (2005) Modelling glandular epithelial cancers in three-dimensional cultures. Nat Rev Cancer 5: 675-688.
25. Reginato MJ, Muthuswamy SK, (2006) Illuminating the center: mechanisms regulating lumen formation and maintenance in mammary morphogenesis. J Mammary Gland Biol Neoplasia 11: 205-211.
26. Debnath J, Mills KR, Collins NL, Reginato MJ, Muthuswamy SK, et al. (2002) The role of apoptosis in creating and maintaining luminal space within normal and oncogene-expressing mammary acini. Cell 111: 29-40.
27. Debnath J, Walker SJ, Brugge JS, (2003) Akt activation disrupts mammary acinar architecture and enhances proliferation in an mTOR-dependent manner. J Cell Biol 163: 315-326.
28. Muthuswamy SK, Li D, Lelievre S, Bissell MJ, Brugge JS, (2001) ErbB2, but not ErbB1, reinitiates proliferation and induces luminal repopulation in epithelial acini. Nat Cell Biol 3: 785-792.
29. Gonzalez-Polo RA, Carvalho G, Braun T, Decaudin D, Fabre C, et al. (2005) PK11195 potently sensitizes to apoptosis induction independently from the peripheral benzodiazepin receptor. Oncogene 24: 7503-7513.
30. Lee GY, Kenny PA, Lee EH, Bissell MJ, (2007) Three-dimensional culture models of normal and malignant breast epithelial cells. Nat Methods 4: 359-365.
31. Boulares AH, Yakovlev AG, Ivanova V, Stoica BA, Wang G, et al. (1999) Role of poly(ADP-ribose) polymerase (PARP) cleavage in apoptosis. Caspase 3-resistant PARP mutant increases rates of apoptosis in transfected cells. J Biol Chem 274: 22932-22940.
32. Chen J, Miller EM, Gallo KA, (2010) MLK3 is critical for breast cancer cell migration and promotes a malignant phenotype in mammary epithelial cells. Oncogene 29: 4399-4411.
33. Herr R, Wohrle FU, Danke C, Berens C, Brummer T, (2011) A novel MCF-10A line allowing conditional oncogene expression in 3D culture. Cell Commun Signal 9: 17.
34. Santidrian AF, Cosialls AM, Coll-Mulet L, Iglesias-Serret D, de Frias M, et al. (2007) The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells. Haematologica 92: 1631-1638.
35. Rechichi M, Salvetti A, Chelli B, Costa B, Da Pozzo E, et al. (2008) TSPO over-expression increases motility, transmigration and proliferation properties of C6 rat glioma cells. Biochim Biophys Acta 1782: 118-125.
36. Sharaf el dein O, Mayola E, Chopineau J, Brenner C, (2011) The adenine nucleotide translocase 2, a mitochondrial target for anticancer biotherapy. Curr Drug Targets 12: 894-901.
37. Kim EH, Koh EH, Park JY, Lee KU, (2010) Adenine nucleotide translocator as a regulator of mitochondrial function: implication in the pathogenesis of metabolic syndrome. Korean Diabetes J 34: 146-153.
38. Floridi A, Paggi MG, D'Atri S, De Martino C, Marcante ML, et al. (1981) Effect of lonidamine on the energy metabolism of Ehrlich ascites tumor cells. Cancer Res 41: 4661-4666.
39. Milane L, Duan Z, Amiji M, (2011) Therapeutic efficacy and safety of paclitaxel/lonidamine loaded EGFR-targeted nanoparticles for the treatment of multi-drug resistant cancer. PLoS One 6: e24075.
40. Belzacq AS, El Hamel C, Vieira HL, Cohen I, Haouzi D, et al. (2001) Adenine nucleotide translocator mediates the mitochondrial membrane permeabilization induced by lonidamine, arsenite and CD437. Oncogene 20: 7579-7587.
41. Ravagnan L, Marzo I, Costantini P, Susin SA, Zamzami N, et al. (1999) Lonidamine triggers apoptosis via a direct, Bcl-2-inhibited effect on the mitochondrial permeability transition pore. Oncogene 18: 2537-2546.
42. Ansseau M, von Frenckell R, Cerfontaine JL, Papart P, (1991) Pilot study of PK 11195, a selective ligand for the peripheral-type benzodiazepine binding sites, in inpatients with anxious or depressive symptomatology. Pharmacopsychiatry 24: 8-12.
43. Pronzato P, Amoroso D, Bertelli G, Conte PF, Cusimano MP, et al. (1989) Phase II study of lonidamine in metastatic breast cancer. Br J Cancer 59: 251-253.